I really appreciate your posts @Chau165, I don't know where you...

I really appreciate your posts @Chau165, I don't know where you find all of this stuff but thank you. What us "hole drillers" need now, is someone in plain speak to highlight how this improves our (here I assume that if you are holding you are in this camp) understanding of the science behind Mesoblast and its therapies turning out to be winners.
I read it as fantastically positive. But I am biased.
I thought that SI had already made it clear that Rem-l was for acute SRGvHD and not to given before the transplant. To be fair to the paper it did seem to question some of the conclusions from the trials when looking at all the trials in a meta-analysis. This is above my pay grade and would welcome some constructive observations from the more cerebral contributors .
Putting that to one side, there have been some great posts (sorry not to reference) about this market size. This paper seems positively gushing about the effects MSC can have in IBS diseases.
"More robust results were obtained in inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis where MSCs demonstrate a great efficacy"
If anybody would care to reply with the market size of IBS it would help put into perspective the opportunity of this area of treatment when compared with the above.
I am going to risk getting a bit of kicking by also challenging the use of meta analysis with GvHD. My understanding of meta analysis is that looks at the treatment effect across all independent studies. OK perhaps for a big subject such as Heart but with our tiny GvHD I wonder if the meta data gleaned, is tainted by poorly run trials or MSC given at the wrong time, wrong cohort or wrong level of potency. Look these are questions not statements as I am not qualified. It is just over the year I have been following Mesoblast, I have got the impression that the learning curve has been rather steep for the company and they are experts in the field.
Anyway, IBS seems to come across as a massive win and from what I understand from other posts, could be in the shops in the next couple of years. As for SRGvHD, it does say a lot of positive things and its last question about MOA? Well I am sure that has been a lot of information on MOA published recently and brought on to HC. Perhaps we should send then a link to this forum?
The paper goes on about treatment for sepsis, ARDS, Acute lung injury and I think how to improve Arsenal's midfield. I also found out that like Dr Dolittle, MSC can talk not to other animals but to other cells.
"MSCs can communicate with nearby cells through secretion of exosomes, small membrane vesicles that contain bioactive molecules like proteins, lipids, mRNAs, microRNAs and mitochondria (69). These molecules can be transferred and reprogram the recipient cells (77). Several studies demonstrated that MSCs, through secretion of exosomes, modify macrophage phenotype and have beneficial effects on inflammatory diseases."
Yet again the importance of MSCs treating inflammation highlights the potential of how many illnesses, diseases or infections where inflammation becomes an acute issue can benefit for Mesoblast developed therapies.
We all get excited by a sudden spike at the end of the day on the share price.
Well when you get a paper like this, which is not sponsored by Mesoblast, and if I have understood it even 30%, it is screaming at us...
The Science works and its benefits are just being better understood. With that understanding will come commercialisation of effective treatments that also DO NO HARM!
So if anyone care to pick apart this paper while we wait for Novartis, FDA and the market do confirm what we already know, I would appreciate the opportunity to learn.
Its gone midnight in Australia so you should all be tucked up. However when you awake, answers please before breakfast. Also 1 1/2 weeks since we were told a few weeks. By my reckoning, that may even be a few days now.
Fingers crossed for all you May option holders, would be interested in how those prices play out, at big spike in those? Well that would be very interesting.
Regards
Yelrom